title: The nongenotropic synthetic ligand 4-estren-3alpha17beta-diol is a high-affinity genotropic androgen receptor agonist.
abstract: The nongenotropic ligand estren (Science 298:843-846, 2002) was evaluated for its transcriptional activity mediated by the human androgen receptor (AR). Our results show that estren can bind, translocate, transactivate, and regulate two known target genes of AR in androgen-responsive cell lines. Estren binds recombinant AR with 10-fold higher affinity than either estrogen receptor (ER)-alpha or ERbeta. Estren-bound AR can translocate AR to the nucleus and stimulate the androgen response element-luciferase reporter activity with an efficacy similar to that of androgen. Estren also increased the expression of prostate-specific antigen (PSA) in a dose-dependent manner in human LnCaP cells. Using chromatin immunoprecipitation analysis, we show that the estren-bound AR coimmunoprecipitates with a region of the PSA gene promoter. Therefore, cotreatment with an AR antagonist, bicalutamide, blocked the estren-induced increase in PSA expression. In contrast, phosphoinositol 3-kinase inhibitor wortmannin, or extracellular signal-regulated kinase inhibitor 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophynyltio)butadiene (U0126), and ER antagonist ICI-182780 failed to block the effects of estren. In vivo analysis of estren's action on male-orchidectomized ICR mice revealed estren's AR agonist actions on the levator ani and seminal vesicle target tissues. Taken together, our results reveal the hitherto unidentified genotropic action of estren mediated by AR in androgen-responsive cells and tissues.
authors.affiliation: Musculoskeletal Research, Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN 46225, USA. Krishnan_Gary@lilly.com
authors.forename: V
authors.initials: V
authors.lastname: Krishnan
authors.forename: H A
authors.initials: HA
authors.lastname: Bullock
authors.forename: B C
authors.initials: BC
authors.lastname: Yaden
authors.forename: M
authors.initials: M
authors.lastname: Liu
authors.forename: R J
authors.initials: RJ
authors.lastname: Barr
authors.forename: C
authors.initials: C
authors.lastname: Montrose-Rafizadeh
authors.forename: K
authors.initials: K
authors.lastname: Chen
authors.forename: J A
authors.initials: JA
authors.lastname: Dodge
authors.forename: H U
authors.initials: HU
authors.lastname: Bryant
mesh_terms: D000728:Androgens; D045744:Cell Line, Tumor; D004797:Enzyme-Linked Immunosorbent Assay; D004963:Estrenes / Q000378:metabolism* / Q000494:pharmacology*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000235:genetics; D007700:Kinetics; D008297:Male; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms; D021381:Protein Transport; D012333:RNA, Messenger / Q000235:genetics; D011944:Receptors, Androgen / Q000378:metabolism*; D011994:Recombinant Proteins / Q000378:metabolism; D014162:Transfection
chemical_list: C468666:4-estren-3,17-diol; D000728:Androgens; D004963:Estrenes; D012333:RNA, Messenger; D011944:Receptors, Androgen; D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I; D017430:Prostate-Specific Antigen